The American Journal of Managed Care4d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...
Pharmaceutical Technology1d
Nivolumab biosimilar by Amgen for Metastatic Melanoma: Likelihood of Approval
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
I-Mab stock jumps 15% following pipeline update
Shares of I-Mab (NASDAQ:IMAB) jumped 15% in midday trading Monday after the biotech company said it plans to focus on ...
Targeted Oncology10d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Monthly Prescribing Reference5d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
News Medical on MSN2d
Study identifies best imaging methods for evaluating brain tumor response in melanoma patients
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...
Targeted Oncology5d
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...
FiercePharma5d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Improving predictions about brain cancer outcomes with the right imaging criteria
A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...
Becker's Hospital Review7d
FDA approves injectable version of popular cancer drug
The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...